RET异常癌症对靶向治疗的适应性抗药性机制。

IF 10 1区医学 Q1 ONCOLOGY Clinical Cancer Research Pub Date : 2025-03-17 DOI:10.1158/1078-0432.CCR-24-3734

Sandra Ortiz-Cuaran, Camille Leonce

{"title":"RET异常癌症对靶向治疗的适应性抗药性机制。","authors":"Sandra Ortiz-Cuaran, Camille Leonce","doi":"10.1158/1078-0432.CCR-24-3734","DOIUrl":null,"url":null,"abstract":"The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent human epidermal growth factor receptor 3 (HER3) activation constitutes a therapeutic vulnerability of adaptive resistance to RET-targeted therapies in RET-altered cancers, highlighting a promising strategy to improve RET inhibitor tumor responses. See related article by Katayama et al., p. 1127.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"958-959"},"PeriodicalIF":10.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mechanisms of Adaptive Resistance to Targeted Therapy in RET-Aberrant Cancers.\",\"authors\":\"Sandra Ortiz-Cuaran, Camille Leonce\",\"doi\":\"10.1158/1078-0432.CCR-24-3734\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent human epidermal growth factor receptor 3 (HER3) activation constitutes a therapeutic vulnerability of adaptive resistance to RET-targeted therapies in RET-altered cancers, highlighting a promising strategy to improve RET inhibitor tumor responses. See related article by Katayama et al., p. 1127.\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\" \",\"pages\":\"958-959\"},\"PeriodicalIF\":10.0000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.CCR-24-3734\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.CCR-24-3734","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

适应性或获得性抗药性限制了靶向疗法在癌基因驱动的癌症中的成功，导致疾病进展。最近的一项研究报告称，YAP 依赖性 HER3 激活是 RET 改变的癌症对 RET 靶向疗法产生适应性耐药性的一个治疗漏洞，凸显了改善 RET 抑制剂肿瘤反应的一种有前景的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Mechanisms of Adaptive Resistance to Targeted Therapy in RET-Aberrant Cancers.

The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent human epidermal growth factor receptor 3 (HER3) activation constitutes a therapeutic vulnerability of adaptive resistance to RET-targeted therapies in RET-altered cancers, highlighting a promising strategy to improve RET inhibitor tumor responses. See related article by Katayama et al., p. 1127.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.